The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers

NCT05421923 ↗

Phase 1 Completed 32 enrolled Shanghai SIMR Biotechnology Co., Ltd.

RandomizedSequentialTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled phase I bridging study to evaluate the PK, PD, safety and tolerability of SR1375 in healthy subjects.

Timeline

Start: 2022-06-24
Primary completion: 2022-10-05
Completion: 2022-10-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SR1375	Unknown	—	Oral

Indications

No indication recorded.